Protease‐resistant peptides for targeting and intracellular delivery of therapeutics

Maria C. Lucana, Yolanda Arruga, Emilia Petrachi, Albert Roig, Roberta Lucchi, Benjamí Oller‐salvia

Producció científica: Article en revista indexadaArticle de revisió (sistemàtica)Avaluat per experts

20 Cites (Scopus)

Resum

Peptides show high promise in the targeting and intracellular delivery of next-generation bio- and nano-therapeutics. However, the proteolytic susceptibility of peptides is one of the major limitations of their activity in biological environments. Numerous strategies have been devised to chemically enhance the resistance of peptides to proteolysis, ranging from N- and C-termini protection to cyclization, and including backbone modification, incorporation of amino acids with non-canonical side chains and conjugation. Since conjugation of nanocarriers or other cargoes to peptides for targeting and cell penetration may already provide some degree of shielding, the question arises about the relevance of using protease-resistant sequences for these applications. Aiming to answer this question, here we provide a critical review on protease-resistant targeting peptides and cell-penetrating peptides (CPPs). Two main approaches have been used on these classes of peptides: enantio/retro-enantio isomerization and cyclization. On one hand, enantio/retro-enantio isomerization has been shown to provide a clear enhancement in peptide efficiency with respect to parent L-amino acid peptides, especially when applied to peptides for drug delivery to the brain. On the other hand, cyclization also clearly increases peptide transport capacity, although contribution from enhanced protease resistance or affinity is often not dissected. Overall, we conclude that although conjugation often offers some degree of protection to proteolysis in targeting peptides and CPPs, modification of peptide sequences to further enhance protease resistance can greatly increase homing and transport efficiency.
Idioma originalAnglès
Número d’article2065
Nombre de pàgines16
RevistaPharmaceutics
Volum13
Número12
DOIs
Estat de la publicacióPublicada - de des. 2021

Fingerprint

Navegar pels temes de recerca de 'Protease‐resistant peptides for targeting and intracellular delivery of therapeutics'. Junts formen un fingerprint únic.

Com citar-ho